euro-infectious-diseases-2017-scientifictracks-abstracts

19 / 24

Page 44
Notes:
conferenceseries.com
Volume 5, Issue 6(Suppl) J Infect Dis Ther, an open access journal
ISSN: 2332-0877 Euro Infectious Diseases 2017
September 07-09, 2017
September 07-09, 2017 | Paris, France
Infectious Diseases
6th Euro-Global Conference on
Targeting RNA binding proteins: A versatile platform for the discovery and development of new antivirals
Jamal Tazi
University of Montpellier, France
ABX464 is a first-in-class, novel, small molecule inhibiting HIV replication through an entirely new mechanism of action. For
the first time in the treatment of HIV, this molecule could reduce or eliminate the viral reservoirs, and thus potentially deliver
a long lasting reduction in the viral load of HIV-patients., ABIVAX designed ABX464 with the goal of targeting the viral reservoirs
of immune cells with integrated genetic material from the HIV-virus. These reservoirs are not affected by current antiretroviral
therapies, and lead to viral load rebound once treatment is stopped. ABX464 inhibits the biogenesis of viral RNA required for the
replication of the HIV virus by targeting the Cap Binding Complex (CBC). During replication HIV RNA is first spliced to give rise
to spliced RNA from which essential auxiliary proteins, like Rev and Tat proteins, are synthesized but later during infection unsliced
viral RNA are produced to generate structural protein and viral genome. ABX464 by stabilizing CBC complex on HIV RNA prevent
the synthesis of unspliced RNA.
This unique mode of action and the preclinical data to-date suggest that ABX464 has the potential to:
Reduce or eliminate the viral reservoirs in patients with HIV
Induce long term control of the viral load
Prevent the emergence of HIV mutants that are resistant to treatment
Be less frequently administered over a shorter period than standard treatments
Reduce healthcare costs and offer broader access to treatment.
ABX464 is the first candidate molecule coming from ABIVAX’s proprietary antiviral platform and chemical library. This library
of more than one thousand small molecules targets the formation of RNP’s in the nucleus or the cytoplasm of the infected cell
during viral infection. Indeed, to replicate, viruses need to generate RNA-Protein complexes (RNP) from the host cell material. RNP
complexes are composed of viral RNA and cellular and viral proteins. Those complexes can “hijack” the cellular machinery of the host
cells to express viral RNA and generate new viruses. This approach can be applied to any type of viruses.
ABX311 is the secondmolecule coming from the ABIVAX antiviral platform. ABX311 is a small molecule able to inhibit Chikungunya
viral replication in vitro with an IC50 in the nanomolar range. ABX311 will enter preclinical development Q4 2017.
Biography
Jamal Tazi is Professor of Functional Genomics at the University of Montpellier and Deputy Director of the Health Centre Biology "Rabelais" responsible for
education and training. For 20 years, he led the team "messenger RNA metabolism in metazoans" within the Institute for Molecular Genetics in Montpellier (IGMM)
where he made important contributions to understand the fundamental mechanisms of the expression of our genes and editing of their products. These discoveries
are used today in the medical field through the development of a new therapy based on the use of small molecules to fight against viral infections. To ensure
the transition between basic and applied research, and also to support these innovative projects to clinical stage, Hel founded in 2008 the company Splicos and
established its partnership with public institutions as a cooperative laboratory where, he became the Scientific Director
Jamal Tazi, J Infect Dis Ther 2017, 5:6(Suppl)
DOI: 10.4172/2332-0877-C1-032